Etoposide: four decades of development of a topoisomerase II inhibitor

By Hande K.R.  

European Journal of Cancer, Vol. 34, Iss. 10, 1998-09 ,pp. : 1514-1521

Elsevier

Access to resources Recommend Favorite

Phase II study of XR 5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with non-small cell lung cancer

By Dittrich C.   Coudert B.   Paz-Ares L.   Caponigro F.   Salzberg M.   Gamucci T.   Paoletti X.   Hermans C.   Lacombe D.   Fumoleau P.   on behalf of the European Organization for Research and Treatment of Cancer-Early Clinical Studies Group/New Drug Development Programme EORTC-ECSG/NDDP  

European Journal of Cancer, Vol. 39, Iss. 3, 2003-02 ,pp. : 330-334

Elsevier

Access to resources Recommend Favorite

Etoposide, Topoisomerase II and Cancer

By  

Current Medicinal Chemistry - Anti-Cancer Agents, Vol. 5, Iss. 4, 2005-01 ,pp. : 363-372

Bentham Science Publishers

Access to resources Recommend Favorite

Topoisomerase I and II Inhibitors: A Patent Review

By  

Recent Patents on Anti-Cancer Drug Discovery, Vol. 11, Iss. 4, 2016-11 ,pp. : 401-423

Bentham Science Publishers

Access to resources Recommend Favorite

Phase II trial with ISIS 5132 in patients with small-cell (SCLC) and non-small cell (NSCLC) lung cancer. A European Organization for Research and Treatment of Cancer (EORTC) Early Clinical Studies Group report

By Coudert B.   Anthoney A.   Fiedler W.   Droz J.P.   Dieras V.   Borner M.   Smyth J.F.   Morant R.   de Vries M.J.   Roelvink M.   Fumoleau P.  

European Journal of Cancer, Vol. 37, Iss. 17, 2001-01 ,pp. : 2194-2198

Elsevier

Access to resources Recommend Favorite